Objective: ShenQi compound (SQC) is a traditional herbal formula, which has been used to
treat Type 2 diabetes mellitus (T2DM) and complications for years. The aim of this study was to explore
the preventive and protective effects of SQC recipe on the skeletal muscle of diabetic macrovasculopathy
mice, which provides a theoretical basis for the clinical use of this formula.
Methods: We evaluated the effect of SQC in a diabetic vasculopathy mouse model by detecting a series
of blood indicators (blood glucose, lipids and insulin) and performing histological observations.
Meanwhile, we explored the molecular mechanism of SQC treatment on skeletal muscle by genome
Results: The results indicated that SQC could effectively improve blood glucose, serum lipids (total
cholesterol (TC), Triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density
lipoprotein cholesterol (LDL-C)) and insulin (INS) levels in diabetic vasculopathy mice, as well as
alleviating skeletal muscle tissue damage for diabetic macrovasculopathy. Meanwhile, compared with
rosiglitazone, SQC showed a better effect on blood glucose fluctuation. Moreover, the gene microarray
analysis indicated that SQC might improve T2DM by affecting biological functions related to cell
death and cell adhesion. Moreover, 7 genes (Celsr2, Rilpl1, Dlx6as, 2010004M13Rik, Anapc13,
Gm6097, Ddx39b) might be potential therapeutic targets of SQC.
Conclusion: All these results indicate that SQC is an effective preventive and protective drug for
skeletal muscle in diabetic macrovasculopathy, and could alleviate skeletal muscle tissue damage
through affecting biological functions related to cell death and cell adhesion.